A non-invasive, yet highly effective solution, Brainsway can make a difference in the wellbeing and health of millions of patients worldwide. Brainsway's technology releases millions of patients from a bleak cycle of insufficiently effective treatments and unpleasant side effects. Brainsway's high efficacy for the treatment of Major Depressive Disorder was validated by the FDA, which has granted a
wide indication for the treatment of Major Depressive Disorder patients. The technology is also safe, with no systemic effects or long-term side effects, and highly convenient, requiring only brief daily sessions over a couple of weeks. Brainsway has gained CE approval for the following indications:
Major Depressive Disorder (FDA indication)
Bipolar Depression
Post-Traumatic Stress Disorder
Schizophrenia (negative symptoms)
Parkinson's Disease
Chronic Pain
The technology has already been applied in thousands of cases worldwide in the framework of clinical studies. It has also been enthusiastically embraced by leading research institutions worldwide, with over 60 clinical trials performed.
